

## Roche to acquire Ignyta, 4/18

**April 2018**—Roche will acquire San Diego-based Ignyta for \$27.00 per share in cash, or \$1.7 billion.

Ignyta, which will continue its operations in San Diego, focuses on precision medicine in oncology aiming to test, identify, and treat patients with cancers harboring specific rare mutations. The company's investigational drug entrectinib, a selective central nervous system-active tyrosine kinase inhibitor for the treatment of patients with solid tumors that harbor ROS1 or NTRK fusions, will expand Roche's portfolio of oncology medicines.

[Roche](#), 650-225-1000